Skip to content
Screener

Pelthos Therapeutics PTHS Q4 2025 Annual earnings

Reported March 19, 2026 · Before market open

Revenue$9.4MBeat by $298.5K
EPS-$2.83Beat by $1.12
Revenue estimate$9.1M
EPS estimate-$3.95

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$18.0M
EPS estimate-$2.90

Financials

Q4 2025

Income statement

See full
Revenue$9.4M—
Gross profit$7.7M—
Operating income-$12.0M-558%
Net income-$21.7M-1,025%

Balance sheet

See full
Cash & equivalents$18.0M+3,404%
Total debt$3.4M—
Total equity$38.9M+1,533%
Total assets$130.4M+9,425%

Cash flow

See full
Operating cash flow-$6.3M-833%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$95.69M—
Enterprise value$81.1M—
P/S5.7×—

Profitability

See full
Gross margin76.3%—
Operating margin-193.1%—
Net margin-257.9%—

Returns & leverage

See full
Debt / equity0.1×—
Current ratio2.1×+1.7×

FAQ

When did Pelthos Therapeutics report Q4 2025 earnings?
Pelthos Therapeutics (PTHS) reported Q4 2025 earnings on March 19, 2026 before market open.
What were Pelthos Therapeutics's Q4 2025 revenue and EPS?
Pelthos Therapeutics reported revenue of $9.4M and eps of $-2.83 for Q4 2025.
Did Pelthos Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $9.1M by $298.5K. EPS beat the consensus estimate of $-3.95 by $1.12.
Where can I find Pelthos Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001919246-26-000014) and the 10-K periodic report (0001919246-26-000013) directly on SEC EDGAR. The filing index links above go to sec.gov.